ProKidney
ProKidney Streamlines Phase 3 Program to Expedite U.S. Approval of Rilparencel for Chronic Kidney Disease
ProKidney, rilparencel, chronic kidney disease, CKD, cell therapy, RMAT designation, FDA approval, Phase 3 trial
ProKidney Suspends One Phase 3 CKD Cell Therapy Trial Deemed Surplus for FDA Approval
ProKidney, CKD, cell therapy, Phase 3 trial, FDA approval